David Darling has a dig at DHB delays

David Darling has a dig at DHB delays
David Darling: Disappointed with slow adoption (Image: Supplied)
Brent Melville
Pacific Edge’s cancer diagnostic products have made headway into the US healthcare sector over the past several years, but many New Zealand patients continue to be shut out by the bureaucracy of local DHBs, the company says.Last June, the NZX-listed firm announced giant US healthcare group Kaiser Permanente had approved its Cxbladder products for use by urologists to monitor patients for bladder cancer. A month later it announced Cxbladder tests will be covered by the Centers for Medicare and Medicaid Services (CMS) across the US mar...

More Markets

NZ sharemarket up 0.4% to end the week
Markets Market close

NZ sharemarket up 0.4% to end the week

The S&P/NZX 50 Index closed at 11,794.81, up 48.15 points or 0.41%.

Graham Skellern 05 Jul 2024
Australian shares rally as dollar hits six-month high
Markets Aus Market Wrap

Australian shares rally as dollar hits six-month high

The ASX200 has risen 1.2% to hit a nine-day high.

AAP 05 Jul 2024
NZ sharemarket down, Oz and US stocks climb
Markets Market close

NZ sharemarket down, Oz and US stocks climb

The S&P/NZX 50 Index closed at 11,746.66, down 44.26 points or 0.38%.

Graham Skellern 04 Jul 2024
Summerset anticipates flat 1H underlying profit
Markets

Summerset anticipates flat 1H underlying profit

The company is NZ's best-performing retirement village operator.

Gregor Thompson 04 Jul 2024